SHORT COMMUNICATION

Punctate Palmoplantar Keratoderma Type 1: A Novel AAGAB Mutation and Efficacy of Etretinate

Toshifumi Nomura1, Akihiro Yoneta2, Elizabeth Pohler3, Shotaro Suzuki1, Rinko Osawa1, Osamu Mizuno1, Yuka Ohguchi1, Yukiko Nomura1, Toshiharu Yamashita2, W. H. Irwin McLean1 and Hiroshi Shimizu1

Departments of Dermatology, 1Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, 2Sapporo Medical University School of Medicine, Sapporo, Japan and 3Centre for Dermatology and Genetic Medicine, College of Life Sciences and College of Medicine, Dentistry and Nursing, University of Dundee, Dundee, UK. E-mail: nomura@huhp.hokudai.ac.jp
Accepted Feb 26, 2014; Epub ahead of print Feb 27, 2014

Punctate palmoplantar keratoderma type 1 (PPKP1, OMIM#148600), also known as the Buschke-Fischer-Braurer type, is a rare form of palmoplantar keratoderma that is autosomal dominantly inherited (1). PPKP1 is clinically characterised by multiple punctate hyperkeratotic papules affecting the palmar and plantar skin, with considerable phenotypic variation among patients (2). These circumscribed papules gradually coalesce and increase in number with age (2). The lesions typically start to appear in early adolescence but sometimes develop later in life. In 2012, linkage analysis and whole-exome sequencing identified heterozygous null mutations within AAGAB as a cause of PPKP1 (2, 3). AAGAB encodes α- and γ-adaptin binding protein p34, which is involved in clathrin-mediated vesicle transport (2). Loss-of-function mutations in AAGAB result in haploinsufficiency of p34 (2). To date, 20 AAGAB null variants have been identified in Scottish, Irish, English, German, Tunisian, Chinese Mexican and Japanese populations (2–8). Here we report a Japanese case with PPKP1 carrying a novel AAGAB null mutation.

CASE REPORT

An 80-year-old Japanese woman presented with numerous hyperkeratotic lesions on the palms and soles. They had gradually increased in number since the symptoms first emerged in the first decade of life. She had a previous medical history of diabetes mellitus but was otherwise healthy. Physical examination showed hundreds of asymptomatic keratotic papules up to 5 mm in diameter on the palmoplantar regions (Fig. 1A). On the soles, the weight-bearing areas were mainly affected. Some of the papules were coalesced to form larger plaques. The patient had a family history of the disorder, with one of her 2 children also being affected. Histology of the papule sampled from the left palm showed hypergranulosis and hyperkeratosis with a well-defined central epidermal depression (Fig. 1B). Parakeratosis was not a feature. Immunohistochemical staining for Ki-67 showed continuous staining of the basal keratinocytes of the affected epidermis (Fig. 1C). Taken together, a diagnosis of PPKP1 was made. Mutation analysis of AAGAB was subsequently performed. In brief, genomic DNA of the patient was obtained from saliva using the Oragene DNA Self-Collection Kit (DNA Genotek, Kanata, ON, Canada) and all exons and exon-intron boundaries of AAGAB were amplified and sequenced as described previously (2). The patient gave written informed consent for mutation analysis in compliance with the Declaration of Helsinki Principles. This study was approved by the Medical Ethics Committee of the Hokkaido University Graduate School of Medicine. Mutation analysis of AAGAB revealed that the patient was heterozygous for a previously unreported frameshift mutation, c.174delC (Fig. S1), in exon 2 of the gene. The 1-bp deletion results in a premature termination codon (PTC) at 51 amino acids downstream of the mutation (p.Asn59Ilefs*51), presumably causing haploinsufficiency of AAGAB. This mutation was not detected in 50 ethnically matched control individuals.

http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1832

Fig. 1. Numerous asymptomatic keratotic papules (arrowheads) on the palms (A). Hyperkeratosis and hypergranulosis with a well-defined central epidermal depression (H&E stain, original magnification × 20) (B). Significant decreases in the number of keratotic papules (arrowheads) and flattening of them were observed within a month after initiation of oral etretinate therapy (C). Immunohistochemical study shows a significant increase in the number of basal keratinocytes positive for Ki-67 in the patient’s epidermis compared to control (anti-Ki-67 antibody, original magnification, × 100) (D).
Thus, the diagnosis of PPKP1 was further confirmed by genetic testing. Thirty mg/day of oral etretinate (Tigason®) dramatically reduced the number of keratotic papules in the patient within a month of initiation of therapy (Fig. 1C).

**DISCUSSION**

In this study, we have identified a novel AAGAB null mutation. To our knowledge, this is the second PTC-causing mutation in AAGAB identified in the Japanese population. Thus, our results further support the recent discoveries which suggest that loss-of-function mutations in AAGAB cause PPKP1 (2–8). This study brings the total number AAGAB null variants to 21. However, previous studies have identified no genotype-phenotype correlations. Moreover, patients with PPKP1 have been reported to show diverse phenotypic severity, even when they carry a same PTC-causing mutation (2). The phenotypes differ among patients in the age of onset and in the severity of the palmoplantar skin lesions. Aging and environmental factors could play greater roles in determining the disease severity than could the context of the AAGAB mutation carried by patients. Indeed, the lesions have gradually increased in number with age in the present case.

The pathomechanism of PPKP1 has not been fully elucidated. In this study, we performed immunohistochemical staining for Ki-67 of the palm skin of the patient and a control individual, and it showed a significant increase in the number of basal keratinocytes positively stained for Ki-67 of the palmar skin of the patient and further indicate that the hyperkeratosis seen in PPKP1 is a hyperproliferative hyperkeratosis rather than a retention hyperkeratosis.

Although our patient has not developed any malignancies, there are several reports of malignancy occurring in association with PPKP1 (9), suggesting a causal link between malignancy and AAGAB mutations. However, further investigations using a larger case series are warranted to confirm this finding.

α- and γ-adaptin binding protein p34 is involved in clathrin-mediated pathway that plays a crucial role in the endocytosis and recycling of receptor tyrosine kinases (RTKs) (10). Notably, almost complete knockdown of AAGAB in HaCaT cells was shown to result in markedly increased expression of epidermal growth factor receptor (EGFR) and Axl which are RTKs highly expressed in the skin (2, 5). Therefore, AAGAB null mutations may increase the half-life of several RTKs in basal keratinocytes via impaired clathrin-dependent pathways, leading to a hyperproliferation hyperkeratosis. In contrast, Kiritsi et al. (7) reported that primary keratinocytes derived from a PPKP1 patient harbouring the heterozygous splice-site mutation c.870+1G>A showed no significant increase in expression of EGFR nor of phosphorylated EGFR compared with primary normal human keratinocytes, and those authors speculated that haploinsufficiency of p34, i.e. an approximately 50% reduction in p34, may be insufficient to cause EGFR overexpression. Further studies are warranted to clarify the pathogenesis of PPKP1.

Therapeutic options for PPKP1 are currently limited, but it is of note that oral etretinate effectively resolved the lesions in our case. As there are only a few case reports that show the efficacy of etretinate or acitretin in treating PPKP1 (11), this study gives further evidence that systemic retinoids are effective against this intractable disease.

**ACKNOWLEDGEMENTS**

This work was supported by Grants-in-Aid for Young Scientists (B) 25860925 (T. Nomura) and (B) 24791130 (R. Osawa), both from the Japan Society for the Promotion of Science. The Centre for Dermatology and Genetic Medicine was supported by grants from The Wellcome Trust (092530/Z/10/Z and 098439/Z/12/Z).

The authors declare no conflicts of interest.

**REFERENCES**